AbbVie won’t enforce patents for COVID-19 drug candidate KaletraAbbVie has said it won’t defend patent rights to its HIV therapy Kaletra in the hope that it Share XAbbVie won’t enforce patents for COVID-19 drug candidate Kaletrahttps://pharmaphorum.com/news/abbvie-wont-enforce-patents-for-covid-19-drug-candidate-kaletra/
New combination trial firms up Venclexta’s prospects in AMLAbbVie and Roche have been thrown a lifeline for their Venclexta drug in acute myeloid leukaemia (AML), just Share XNew combination trial firms up Venclexta’s prospects in AMLhttps://pharmaphorum.com/news/new-combination-trial-firms-up-venclextas-prospects-in-aml/
AbbVie’s Kaletra doesn’t work in COVID-19, say Chinese scientistsA clinical trial of AbbVie’s HIV therapy Kaletra conducted by researchers in China has undermined hopes it could Share XAbbVie’s Kaletra doesn’t work in COVID-19, say Chinese scientistshttps://pharmaphorum.com/news/abbvies-kaletra-doesnt-work-in-covid-19-say-chinese-scientists/
AbbVie/Allergan merger cleared in EU with brazikumab sell-offAbbVie and Allergan’s $63 billion merger has been cleared by European regulators, who have approved the sell-off of Share XAbbVie/Allergan merger cleared in EU with brazikumab sell-offhttps://pharmaphorum.com/news/abbvie-allergan-merger-cleared-in-eu-with-brazikumab-sell-off/
AbbVie/Roche’s Venclexta fails in confirmatory AML trialAbbVie and Roche’s Venclexta has failed to significantly improve overall survival in an acute myeloid leukaemia (AML) trial Share XAbbVie/Roche’s Venclexta fails in confirmatory AML trialhttps://pharmaphorum.com/news/abbvie-roches-venclexta-fails-in-confirmatory-aml-trial/
AbbVie’s CEO hails ‘exceptional’ psoriasis drug launch as Humira fadesThe bad news from AbbVie’s full year results was that inflammatory diseases blockbuster Humira “only” made around $19.2 Share XAbbVie’s CEO hails ‘exceptional’ psoriasis drug launch as Humira fadeshttps://pharmaphorum.com/news/abbvies-ceo-hails-exceptional-psoriasis-drug-launch-as-humira-fades/
3 key trends shaping the immunology marketFrom an increase in sales of interleukin inhibitors to the prevalence of biosimilars, this decade has been an Share X3 key trends shaping the immunology markethttps://pharmaphorum.com/views-analysis-market-access/3-key-trends-shaping-the-immunology-market/
Alector launches $208m fundraiser for Alzheimer’s R&D with AbbVieAlector has launched an $208 million stock market offering as it ramps up clinical trials with AbbVie into Share XAlector launches $208m fundraiser for Alzheimer’s R&D with AbbViehttps://pharmaphorum.com/news/alector-launches-208m-fundraiser-as/
Quench targets lupus and rare diseases with R&D into new drug classQuench Bio has emerged from stealth mode with $50 million of committed funding, bidding to be the first Share XQuench targets lupus and rare diseases with R&D into new drug classhttps://pharmaphorum.com/news/uk-biotech-targets/
